1. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938-48. DOI:10.1056/NEJMra1001389
2. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-52. DOI: 10.1038/35021093.
3. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796-804. DOI: 10.1200/jco.2011.38.8595
4. Fornier M, Fumoleau P. The paradox of triple negative breast cancer: novel approaches to treatment. Breast J. 2012;18(1):41-51. DOI: 10.1111/j.1524-4741.2011.01175.x
5. Masuda N, Lee S-J, Ohtani S, Im Y-H, Lee E-S, Yokota I, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. New England Journal of Medicine. 2017;376(22):2147-59. DOI: 10.1056/NEJMoa1612645
6. Takahashi S, Moriya T, Ishida T, Shibata H, Sasano H, Ohuchi N, et al. Prediction of breast cancer prognosis by gene expression profile of TP53 status. Cancer Sci. 2008;99(2):324-32. DOI: 10.1111/j.1349-7006.2007.00691.x
7. Yamaguchi S, Takahashi S, Mogushi K, Izumi Y, Nozaki Y, Nomizu T, et al. Molecular and clinical features of the TP53 signature gene expression profile in early-stage breast cancer. Oncotarget. 2018;9(18):14193-206. DOI: 10.18632/oncotarget.24447
8. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401-4. DOI: 10.1158/2159-8290.Cd-12-0095
9. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1. DOI: 10.1126/scisignal.2004088
10. Goldman MJ, Craft B, Hastie M, Repečka K, McDade F, Kamath A, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nature Biotechnology. 2020;38(6):675-8. DOI: 10.1038/s41587-020-0546-8
11. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48(3):452-8. DOI: 10.1038/bmt.2012.244
12. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37(1):1-13. DOI: 10.1093/nar/gkn923
13. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature Protocols. 2009;4(1):44-57. DOI: 10.1038/nprot.2008.211
14. Fu J, Li K, Zhang W, Wan C, Zhang J, Jiang P, et al. Large-scale public data reuse to model immunotherapy response and resistance. Genome Med. 2020;12(1):21. DOI: 10.1186/s13073-020-0721-z
15. Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nature Medicine. 2018;24(10):1550-8. DOI: 10.1038/s41591-018-0136-1
16. Oshima K, Naoi Y, Kishi K, Nakamura Y, Iwamoto T, Shimazu K, et al. Gene expression signature of TP53 but not its mutation status predicts response to sequential paclitaxel and 5-FU/epirubicin/cyclophosphamide in human breast cancer. Cancer Lett. 2011;307(2):149-57. DOI: 10.1016/j.canlet.2011.03.027
17. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162-74. DOI: 10.1038/nri2506
18. Retseck J, Nasr A, Lin Y, Lin H, Mendiratta P, Butterfield LH, et al. Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma. Journal of Translational Medicine. 2018;16(1):184. DOI: 10.1186/s12967-018-1563-y
19. Gonda K, Shibata M, Ohtake T, Matsumoto Y, Tachibana K, Abe N, et al. Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer. Oncol Lett. 2017;14(2):1766-74. DOI: 10.1186/s12967-018-1563-y
20. Alizadeh D, Trad M, Hanke NT, Larmonier CB, Janikashvili N, Bonnotte B, et al. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res. 2014;74(1):104-18. DOI: 10.1158/0008-5472.Can-13-1545
21. Wang Z, Till B, Gao Q. Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells. Oncoimmunology. 2017;6(7):e1331807. DOI: 10.1080/2162402x.2017.1331807
22. Li L, Li M, Wang X. Cancer type-dependent correlations between TP53 mutations and antitumor immunity. DNA Repair (Amst). 2020;88:102785. DOI: 10.1016/j.dnarep.2020.102785
23. Zeng Y, Wang CL, Xian J, Ye Q, Qin X, Tan YW, et al. Positive correlation between programmed death ligand-1 and p53 in triple-negative breast cancer. Onco Targets Ther. 2019;12:7193-201. DOI: 10.2147/ott.S209484
24. Liu Z, Jiang Z, Gao Y, Wang L, Chen C, Wang X. TP53 Mutations Promote Immunogenic Activity in Breast Cancer. Journal of Oncology. 2019;2019:5952836. DOI: 10.1155/2019/5952836
25. Aguadé-Gorgorió G, Solé R. Genetic instability as a driver for immune surveillance. J Immunother Cancer. 2019;7(1):345. DOI: 10.1186/s40425-019-0795-6
26. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. New England Journal of Medicine. 2018;379(22):2108-21. DOI: 10.1056/NEJMoa1809615
27. Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im S-A, Yusof MM, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. The Lancet. 2020;396(10265):1817-28. DOI: 10.1016/S0140-6736(20)32531-9
28. Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. New England Journal of Medicine. 2020;382(9):810-21. DOI: 10.1056/NEJMoa1910549
29. Kossai M, Radosevic-Robin N, Penault-Llorca F. Refining patient selection for breast cancer immunotherapy: beyond PD-L1. ESMO Open. 2021;6(5). DOI: 10.1016/j.esmoop.2021.100257
30. Fearon DT. The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance. Cancer Immunol Res. 2014;2(3):187-93. DOI: 10.1158/2326-6066.Cir-14-0002
31. Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nature Reviews Cancer. 2020;20(3):174-86. DOI: 10.1038/s41568-019-0238-1
32. Pan Y, Yu Y, Wang X, Zhang T. Tumor-Associated Macrophages in Tumor Immunity. Front Immunol. 2020;11:583084. DOI: 10.3389/fimmu.2020.583084